LONDON, UK - Jun 15, 2018 -
Check4Cancer
is delighted to announce it has been awarded Diagnostics provider of the year at the
2018 Health Investor Awards
held at the Grosvenor Hotel, London.
Having been nominated for three years in a row, Check4Cancer was praised by the judges for its high quality patient-centred, medically led service with clear targets for an effective one-stop approach diagnostic pathway and its level of clinical audit underpinning the outcomes.
Accepting the award, Prof Gordon Wishart, Chief Medical Officer for Check4Cancer, commented We are thrilled to have been recognised for our commitment to patient focused, reliable early cancer detection. Our best practice diagnostic pathways for breast & skin cancer have given patients rapid access to an accurate and reliable diagnosis, reducing average times to diagnosis and improving patients experience. We would like to thank the Health Investor Awards for recognising that out audited pathways have increased clinical governance in the private sector, and we would like to congratulate all the other finalists.
Check4Cancer enables people to take ownership of their health, and that of their family, by providing cancer services that are innovative, validated and effective. The companys team of cancer specialists has extensive clinical expertise, enabling Check4Cancer to provide award-winning services trusted by leading UK insurance providers and corporate sector clients.
Ends
For further information, contact:
Check4Cancer
Professor Gordon Wishart
E:
gcwishart@check4cancer.com
T: 0800 085 6663
Sciad Communications, Media Relations
Deborah Cockerill / Juliette Craggs
E:
check4cancer@sciad.com
T: +44 (0)20 7470 8801
Notes to Editors
About Check4Cancer
Check4Cancer is the reliable and trusted provider of early cancer detection and genetic services in the UK. The Company offers rapid access to personalised screening and diagnostic services for anyone anxious about a possible cancer diagnosis, as well as genetic testing and counselling for patients at increased risk of hereditary cancer. Check4Cancer covers bowel, breast, cervical, lung, prostate and skin cancer for the private, insured and corporate markets.
Founded in 2007, Check4Cancers nationwide, evidence-based services are supported by audit data and cover 87% of all new cancer incidence in the UK every year. Services can be accessed at over 80 clinics across the UK.
Check4Cancer partners with companies in the UK, USA & Europe, facilitating the offering of cancer screening and awareness as an employee benefit. Existing corporate clients include BBC, Novartis, Sky, VW, Deloitte, HP, Lendlease, Unicredit, Nissan, Volvo and Zurich.
Check4Cancer helps combat one of the fastest growing areas of medical need, as cancer is predicted to impact 1 in 2 people by 20201. Early detection gives patients a better chance of surviving cancer2, and Check4Cancer is the first step.
1
https://www.macmillan.org.uk/documents/aboutus/newsroom/mortality-trends-2013-executive-summary-final.pdf
2
http://www.cancerresearchuk.org/about-cancer/cancer-symptoms/why-is-early-diagnosis-important